Rituximab-induced serum sickness in immunobullous disorders: A case series.
Mehdi GheisariToktam Safari GivElnaz PourgholiShirin ZaresharifiPublished in: Clinical case reports (2024)
Rituximab (RTX) is a chimeric monoclonal anti-CD20 antibody which has gained approval for the treatment of various autoimmune and lymphoproliferative disorders. While RTX-induced minor reactions, including immediate infusion-related reactions, are common, serum sickness is rare. Limited data exist regarding rituximab-induced serum sickness (RISS) in pemphigus vulgaris (PV) and mucous membrane pemphigoid (MMP). We report two cases of RISS following RTX administration in PV and MMP patients. Both patients presented with typical symptoms of serum sickness after RTX infusion, necessitating drug cessation and corticosteroid therapy for resolution. RISS represents a rare complication of RTX therapy. Clinicians should maintain awareness of serum sickness presentations during and post-RTX administration.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- high glucose
- newly diagnosed
- diffuse large b cell lymphoma
- diabetic rats
- peritoneal dialysis
- low dose
- emergency department
- stem cells
- palliative care
- physical activity
- hodgkin lymphoma
- bone marrow
- epstein barr virus
- multiple myeloma
- nk cells
- combination therapy